Author

Claude Haan

University of LuxembourgORCID 0000-0003-0115-9366Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Catherine RolveringiD· 3 shared Iris BehrmanniD· 3 shared Jasmin Renate PreisiD· 3 shared Mélanie KirchmeyeriD· 3 shared Catarina Tinoco PereiraiD· 1 shared Dzeneta HaliloviciD· 1 shared Fabrice TolleiD· 1 shared Joanna Patrycja WróblewskaiD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Catherine RolveringORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler

Jasmin Renate Preis, Catherine Rolvering, Mélanie Kirchmeyer, Catarina Tinoco Pereira, João Faria, Iris Behrmann, Claude Haan

This paper identifies FX-11 as a mitochondrial uncoupler that inhibits melanoma cell growth, including drug-resistant sublines, by altering energy metabolism rather than targeting lactate dehydrogenase.

European Journal of Pharmacology · Mar 25, 2026Peer-reviewedCancer Biology

Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naive and -resistant melanoma cells

Jasmin Renate Preis, Catherine Rolvering, Mélanie Kirchmeyer, Stephanie Kreis, Iris Behrmann, Claude Haan

The paper identifies FK866, a NAMPT inhibitor, as effective against drug-naive and -resistant melanoma cells in various culture conditions without affecting healthy cells.

bioRxiv · Oct 23, 2024 · PreprintCancer Biology

Ferroptosis susceptibility of melanoma cells: dependence on cell-type, acquired drug resistance, and medium composition

Jasmin Renate Preis, Catherine Rolvering, Mélanie Kirchmeyer, Dzeneta Halilovic, Joanna Patrycja Wróblewska, Fabrice Tolle, Iris Behrmann, Claude Haan

This study investigates melanoma cell susceptibility to ferroptosis and drug resistance using novel 3D culture models and medium compositions.

bioRxiv · Aug 12, 2024 · PreprintCancer Biology